JP2002542296A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542296A5
JP2002542296A5 JP2000613446A JP2000613446A JP2002542296A5 JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5 JP 2000613446 A JP2000613446 A JP 2000613446A JP 2000613446 A JP2000613446 A JP 2000613446A JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5
Authority
JP
Japan
Prior art keywords
agent
use according
hematocrit
erythropoietin
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000613446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542296A (ja
Filing date
Publication date
Priority claimed from US09/300,124 external-priority patent/US6171620B1/en
Application filed filed Critical
Publication of JP2002542296A publication Critical patent/JP2002542296A/ja
Publication of JP2002542296A5 publication Critical patent/JP2002542296A5/ja
Pending legal-status Critical Current

Links

JP2000613446A 1999-04-27 2000-04-24 抗腫瘍剤の効力を増大させる方法 Pending JP2002542296A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
US09/300,124 1999-04-27
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
JP2002542296A JP2002542296A (ja) 2002-12-10
JP2002542296A5 true JP2002542296A5 (cg-RX-API-DMAC7.html) 2007-06-28

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000613446A Pending JP2002542296A (ja) 1999-04-27 2000-04-24 抗腫瘍剤の効力を増大させる方法

Country Status (18)

Country Link
US (3) US6171620B1 (cg-RX-API-DMAC7.html)
EP (1) EP1212068A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002542296A (cg-RX-API-DMAC7.html)
KR (1) KR100693796B1 (cg-RX-API-DMAC7.html)
CN (1) CN1188137C (cg-RX-API-DMAC7.html)
AU (1) AU781301B2 (cg-RX-API-DMAC7.html)
BG (1) BG64940B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010082A (cg-RX-API-DMAC7.html)
CA (1) CA2368618C (cg-RX-API-DMAC7.html)
HU (1) HUP0200840A3 (cg-RX-API-DMAC7.html)
IL (1) IL146012A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010899A (cg-RX-API-DMAC7.html)
NO (1) NO20015227L (cg-RX-API-DMAC7.html)
NZ (1) NZ514521A (cg-RX-API-DMAC7.html)
PL (1) PL350918A1 (cg-RX-API-DMAC7.html)
RU (1) RU2271829C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000064455A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108012B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Similar Documents

Publication Publication Date Title
BR0207378A (pt) Tratamento de câncer
NZ621449A (en) Treatment with anti-vegf antibodies
CA2261500A1 (en) Stable oxaliplatin solutions and their use in cytostatic antineoplastic treatment
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
JP2006504723A5 (cg-RX-API-DMAC7.html)
JP2001072577A5 (cg-RX-API-DMAC7.html)
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
JP2002532112A5 (cg-RX-API-DMAC7.html)
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
JP2001522820A5 (cg-RX-API-DMAC7.html)
DE50313653D1 (de) Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
JP2006514116A5 (cg-RX-API-DMAC7.html)
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2002076434A3 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
EP1359909A4 (en) CANCER THERAPY USING TRIPTOLID PRODRUGS
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
FR2812630B1 (fr) Zircone sous forme de poudre fine, hydroxycarbonate de zirconium et leurs procedes de preparation
WO2007149586A3 (en) Anti-c35 antibodies for treating cancer
WO2003007914A3 (en) Biocompatible polymer containing composition for treatment of prostate cancers
JP2009516719A5 (cg-RX-API-DMAC7.html)
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
Lunniss Archaeology at Salango, Ecuador: an Engoroy ceremonial site on the south coast of Manabí
SE0000303D0 (sv) Novel compounds